1121 – 1130 of 1300
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2011
-
Mark
The long-term cognitive outcomes of Alzheimer’s disease — influence of APOE genotype, NSAID therapy, and cholinesterase inhibitor treatment.
2011) 10th International Conference on Alzheimer’s & Parkinson’s Diseases (AD/PD 2011)(
- Contribution to conference › Poster
-
Mark
Complement in the brain
(
- Contribution to journal › Scientific review
-
Mark
CSF amyloid beta 38 as a novel diagnostic marker for dementia with Lewy bodies
(
- Contribution to journal › Article
- 2010
-
Mark
Distinct cerebrospinal fluid amyloid beta peptide signatures in sporadic and PSEN1 A431E-associated familial Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Association of the RAGE G82S polymorphism with Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Ubiquitin carboxy-terminal hydrolase L1 (UCHL1) S18Y polymorphism in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Computerized cognition assessment during acetylcholinesterase inhibitor treatment in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
A beta 40 Oligomers Identified as a Potential Biomarker for the Diagnosis of Alzheimer's Disease
(
- Contribution to journal › Article
-
Mark
The stability of AQT processing speed, ADAS-Cog and MMSE during acetylcholinesterase inhibitor treatment in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
BACE1 gene variants do not influence BACE1 activity, levels of APP or A beta isoforms in CSF in Alzheimer's disease
(
- Contribution to journal › Article